DIVO ETF delivers 6.4% yield via blue-chip dividends and calls
The $7.44 billion DIVO ETF is attracting income investors with a 6.4% monthly yield generated by blending blue-chip dividends with covered-call premiums, but the durability of its underlying payouts varies significantly by holding.
Amplify CWP Enhanced Dividend Income ETF paid a June 30 distribution of $0.18284 per share, maintaining its 6.4% annualized yield. The fund, which manages $7.44 billion in assets, targets investors seeking monthly income without the total return sacrifice typical of pure options-income funds. It has returned 65% over the past five years.
DIVO generates its yield through an active strategy overlaying covered-call premiums on roughly 40 large-cap stocks. The top 10 holdings account for about 49% of the portfolio, heavily weighted toward financials at 24%, technology at 15%, and industrials at 13%. The fund charges a 0.56% expense ratio.
Assessing the underlying cash flow
The sustainability of the distribution depends heavily on the fund's underlying holdings. JPMorgan Chase and Microsoft anchor the portfolio. JPM recently raised its quarterly payout to $1.50, supported by Q2 2026 net income of $21.2 billion, a 23% return on tangible common equity, and a 14.3% common equity tier one ratio. The bank also authorized a new $50 billion buyback effective July 1. Microsoft yields just 0.9% but offers baseline safety, having raised its quarterly dividend to $0.91 in late 2025 on a 39.3% profit margin and 40% Azure growth.
Caterpillar provides a reliable $1.63 quarterly dividend, unbroken for over 25 years, despite 2025 net income falling 17.7% under tariff pressure. Its Q1 2026 earnings rebounded 27% on a record backlog, though the stock's 51% year-to-date gain introduces equity risk. Amgen warrants closer scrutiny from a credit perspective. While $8.1 billion in 2025 free cash flow covers its 2.6% yield, $57.3 billion in total debt at 3.2 times EBITDA leverage introduces structural risk. Biosimilar erosion on Prolia and XGEVA, alongside Medicare pricing pressure on Enbrel, means Amgen's payout depends more on pipeline execution than balance-sheet strength.
For institutional allocators, DIVO represents a pragmatic, hybrid approach to monthly income generation. By actively writing covered calls only when volatility premiums are attractive, the fund avoids the constant drag on upside that plagues passive options-income strategies. The core risk for investors is that a 6.4% yield requires consistent premium collection and flawless dividend coverage from its top holdings. As the diverging credit profiles of JPMorgan and Amgen illustrate, the fund's distribution is only as durable as the cash flows of its heaviest weights.
